STOCK TITAN

Idexx Laboratories Inc - IDXX STOCK NEWS

Welcome to our dedicated page for Idexx Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on Idexx Laboratories stock.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global leader in pet healthcare innovation, providing a broad range of diagnostic and information technology-based products and services to practicing veterinarians across the globe. Headquartered in Southern Maine, the company operates through more than 70 locations worldwide, serving customers in over 175 countries and employing more than 11,000 people.

IDEXX’s primary business focuses on pet health, offering products such as in-clinic diagnostic tests, instrumentation, reference laboratory and telemedicine consultation services, and practice management software. These products enhance veterinarians' ability to provide advanced medical care, improve staff efficiency, and build more economically successful practices. The company is also involved in developing diagnostic tests for the global production animal industry, including poultry and livestock, and tests for the quality and safety of water.

An important recent achievement for IDEXX is the launch of the SNAP® Leish 4Dx® Test, designed to diagnose vector-borne diseases like canine leishmaniosis in regions where these diseases are endemic. This new test will be available in Europe and Asia starting February 2024. Another significant accomplishment is the expansion of the Fecal Dx® antigen testing platform, which includes the addition of Cystoisospora, a common intestinal parasite. This expansion will roll out in North America in March 2024 and globally by the third quarter of 2024.

IDEXX also launched Vello, a software solution aimed at improving communication between veterinary practices and pet owners. This tool supports better health outcomes by engaging pet owners through digital means and is integrated with IDEXX's existing practice management software like ezyVet®, Neo®, and Cornerstone®.

Financially, IDEXX is robust, with a diverse revenue stream sourced from various products and services, including diagnostic equipment, tests, and software solutions. Approximately 35% of its revenue comes from international markets. The company is a member of the S&P 500® Index, highlighting its significant role in the industry.

For more information about IDEXX’s products and services, visit idexx.com.

Rhea-AI Summary

IDEXX Laboratories (NASDAQ: IDXX) announced that Brian McKeon, EVP & CFO, and Michael Lane, EVP & GM of Reference Laboratories and IT, will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 29, 2024, from 10:55 am to 11:25 am (EDT). A live audio webcast will be available on IDEXX's website, with an archived edition accessible later.

The company also announced its 2024 Investor Day on August 15, 2024, at its headquarters in Westbrook, Maine, from 8:00 am to 12:00 pm (EDT). The event will be webcast live, with advance registration required for in-person attendance by institutional investors and analysts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
-
Rhea-AI Summary

IDEXX Laboratories, a global leader in pet healthcare innovation, announced first quarter results with revenue growth of 7% supported by CAG Diagnostics recurring revenue growth of 7%. The company achieved EPS of $2.81 and updated its 2024 revenue guidance to $3,895 million - $3,965 million, and EPS outlook to $10.82 - $11.20.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces the release of its 2024 first quarter results on May 1, 2024, with an analyst conference call scheduled. The Company is a global leader in pet healthcare innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will participate in two upcoming conferences to discuss pet healthcare innovation. Brian McKeon and Tina Hunt will speak at the BofA Securities Animal Health Virtual Summit, while Jay Mazelsky will present at the Raymond James Institutional Investors Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences
-
Rhea-AI Summary
IDEXX Laboratories, Inc. launches Vello, a pet owner engagement solution, showing an average 19% reduction in no-show rates. Vello streamlines communication between veterinary practices and pet owners, improving practice efficiency and client relationships. Key features include automated appointment reminders, health service reminders, online scheduling, pet owner mobile experience, two-way texting, and pre-appointment instructions. Vello will be available for ezyVet, Neo, and Cornerstone software in the U.S. in March 2024 and Canada in Q2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) achieved 9% revenue growth in the fourth quarter of 2023, driven by 11% reported and 10% organic growth in CAG Diagnostics recurring revenue. The company also delivered fourth quarter EPS of $2.32, an increase of 13% as reported and 17% on a comparable basis. IDEXX provided an initial outlook for 2024 revenue of $3,930 million - $4,040 million, reflecting growth of 7.5% - 10.5% reported and 7% - 10% organic, and estimated 2024 EPS of $10.84 - $11.33, an increase of 8% - 13% as reported and on a comparable basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) to release 2023 fourth quarter and full year financial results on February 5, 2024. The company will conduct an analyst conference call at 8:30 a.m. ET. Individuals can access a live webcast and transcript of prepared remarks on the IDEXX website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) expands its Fecal Dx antigen testing platform to include Cystoisospora, a common intestinal parasite affecting young dogs and cats. The new testing offers early and accurate detection of various parasites, with the launch planned for March in North America and globally in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces the global launch of the IDEXX inVue Dx™ Cellular Analyzer, a revolutionary slide-free cellular analyzer for cytology and blood morphology cases in veterinary practices. The platform provides reference-laboratory quality results in 10 minutes, eliminating manual workflow and image analysis steps while generating consistent, clinically actionable results for practitioners and their patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will participate in two upcoming institutional investor events. Jay Mazelsky, President and CEO, will join the Goldman Sachs Healthcare C-Suite Unscripted Conference in New York, New York on January 4, 2024, and will host an Investor and Analyst Session at VMX in Orlando, Florida on January 15, 2024, to highlight IDEXX’s new point of care analyzer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none

FAQ

What is the current stock price of Idexx Laboratories (IDXX)?

The current stock price of Idexx Laboratories (IDXX) is $434.43 as of December 4, 2024.

What is the market cap of Idexx Laboratories (IDXX)?

The market cap of Idexx Laboratories (IDXX) is approximately 35.6B.

What is IDEXX Laboratories, Inc.?

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global leader in pet healthcare innovation, providing a wide range of diagnostic and information technology-based products and services to veterinarians worldwide.

Where is IDEXX Laboratories headquartered?

IDEXX Laboratories is headquartered in Southern Maine, USA.

What are some key products and services offered by IDEXX?

IDEXX offers in-clinic diagnostic tests, reference laboratory and telemedicine consultation services, practice management software, diagnostic tests for production animals, and tests for water safety.

What recent products has IDEXX Laboratories launched?

IDEXX has recently launched the SNAP® Leish 4Dx® Test for vector-borne diseases and expanded its Fecal Dx® antigen testing platform to include Cystoisospora.

How many countries does IDEXX Laboratories serve?

IDEXX Laboratories serves customers in over 175 countries.

How many people does IDEXX Laboratories employ?

IDEXX Laboratories employs more than 11,000 people globally.

What is the new software solution IDEXX launched?

IDEXX launched Vello, a software solution that connects veterinary practices with pet owners through modern digital tools, integrated with existing practice management software.

What percentage of IDEXX's revenue comes from international markets?

Approximately 35% of IDEXX’s revenue comes from international markets.

Is IDEXX part of any major stock index?

Yes, IDEXX Laboratories is a member of the S&P 500® Index.

Where can I find more information about IDEXX's products and services?

For more information, you can visit IDEXX's official website at idexx.com.

Idexx Laboratories Inc

Nasdaq:IDXX

IDXX Rankings

IDXX Stock Data

35.57B
81.34M
0.94%
94.26%
1.98%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
WESTBROOK